Comparative bioavailability of carbamazepine from two slow-release preparations

Area of Science:

• Pharmacokinetics
• Drug bioavailability
• Epilepsy therapeutics

Background:

• Carbamazepine (CBZ) is a widely used antiepileptic drug.
• Slow-release formulations aim to provide stable drug concentrations.
• Comparing bioavailability of different formulations is crucial for therapeutic efficacy.

Purpose of the Study:

• To compare the multiple-dose bioavailability of carbamazepine (CBZ) from two slow-release preparations: Neurotol slow and Tegretol Retard.
• To assess the impact of bioavailability differences on pharmacokinetic parameters and clinical outcomes.

Main Methods:

• A single-blind, randomized, cross-over study involving 21 adult epilepsy patients.
• Serum concentrations of CBZ and its metabolites (CBZE, CBZD) were measured using HPLC after 2-week treatment periods.
• Pharmacokinetic parameters including Cmax, Cmin, Css, and tmax were analyzed.

Main Results:

• Neurotol slow showed 11% higher mean CBZ bioavailability than Tegretol Retard (P = 0.002).
• Significantly higher peak (Cmax), lowest (Cmin), and mean (Css) CBZ concentrations were observed with Neurotol slow.
• No significant differences in serum concentration fluctuation or tmax were found between the two formulations.
• Similar pharmacokinetic profiles were observed for CBZ metabolites.

Conclusions:

• Significant differences exist in the bioavailability of carbamazepine from Neurotol slow and Tegretol Retard slow-release preparations.
• Neurotol slow offers potentially improved bioavailability, leading to higher drug exposure.
• These findings have implications for optimizing carbamazepine therapy in epilepsy patients.